News

Preclinical Research Supports Pridopidine’s Therapeutic Potential

Treatment with pridopidine rescues the function of mitochondria — the cell’s powerhouses — boosting energy production, and reduces oxidative stress in models of Huntington’s disease, preclinical research shows. According to researchers, these findings support the therapeutic potential of pridopidine and its ongoing clinical development. Pridopidine is a small oral…

EveryLife Introduces First of Kind ‘Roadmap’ to ICD Codes

To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…

Galyan Bio Plans to Start Clinical Testing of Oral Therapy in 2022

Galyan Bio plans to initiate a clinical trial of a small molecules candidate that aims to slow the progression of Huntington’s disease next year, working in with Bicoll GmbH. Galyan Bio is developing and optimizing small molecules as oral treatments of Huntington’s and other neurodegenerative disorders, which work by targeting disease-causing mutant…